What is Gameto?
Gameto is a biotechnology company dedicated to advancing women's health through innovative cell engineering. By leveraging a platform developed in collaboration with the laboratory of George Church at Harvard Medical School, the company aims to address significant gaps in reproductive health and fertility. Founded by Dr. Dina Radenkovic and Martin Varsavsky, Gameto bridges the gap between academic research and clinical application. The company's market position is defined by its focus on disruptive, science-led solutions that seek to democratize access to advanced fertility treatments and improve patient outcomes on a global scale.
How much funding has Gameto raised?
Gameto has raised a total of $158M across 5 funding rounds:
Series A
$20M
Other Financing Round
$17M
Series B
$33M
Series C
$44M
Private Equity
$44M
Series A (2022): $20M with participation from Anne Wojcicki, TA Ventures, Lux Capital, Future Ventures, Overwater Ventures, BOLD Capital Partners, Plum Alley, and Robert Nelsen
Other Financing Round (2022): $17M led by BOLD Capital Partners, Insight Partners, Future Ventures, Plum Alley, and Arcadia Investment Partners
Series B (2024): $33M supported by Insight Partners, Two Sigma Ventures, Future Ventures, RA Capital Management, and BOLD Capital Partners
Series C (2025): $44M featuring Arcadia Investment Group, BOLD Capital Partners, Insight Partners, Two Sigma Ventures, RA Capital Management, and Overwater Ventures
Private Equity (2025): $44M, investors not publicly disclosed
Key Investors in Gameto
BOLD Capital Partners
A venture capital firm dedicated to investing in entrepreneurs and technologies that aim to transform the world by disrupting large markets.
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in healthcare and life science companies, utilizing their TechAtlas think tank for scientific analysis.
Two Sigma Ventures
An early-stage venture capital firm that invests in transformative companies leveraging information growth, computing power, and breakthrough therapies.
What's next for Gameto?
With the successful closure of its latest funding round, Gameto is well-positioned to transition its research-stage programs into more advanced clinical trials. The strategic deployment of this capital will likely focus on expanding the company's internal R&D capabilities and strengthening its operational infrastructure to support commercialization efforts. As the firm continues to refine its cell engineering technology, it remains focused on addressing the complex biological challenges inherent in women's health, potentially setting new standards for efficacy and accessibility in the fertility market. The ongoing support from its diverse investor base provides not only financial stability but also the strategic guidance necessary to navigate the regulatory and technical hurdles of the biotech industry.
See full Gameto company page
